Image source: © Timonschneider | Megapixl.com

Highlights

  • CSL is an ASX-listed firm which deals in pharmaceutical and diagnostic products, cell culture media and human plasma fractions
  • CSL’s revenue in 1HFY24 jumped 12% to USD 8,053 million
  • The Vanguard Group, Inc. has the highest stake in CSL with a shareholding of nearly 4.99%

CSL Limited (ASX: CSL) is involved in researching, developing, manufacturing, marketing, and distributing biopharmaceutical products and vaccines. It provides innovative life-saving medications across 100 countries.

In the first half of the financial year 2024 (1HFY24), revenue of CSL increased by 12% YoY to USD 8,053 million, EBITDA jumped 21% YoY to USD 3,042 million and NPAT grew by 17% YoY to USD 1,901 million.

Performance during the six months ended 31 December 2023 was underpinned by portfolio growth of CSL Behring, which registered 23% increase in sales of immunoglobulin products. Driven by international plasma supply, and increase in patient demand, positive performance was witnessed across all geographical regions.

Top 10 shareholders of CSL

The top 10 shareholders of CSL have around 19.75% shareholding in the company, while the top four have nearly 13.53% shareholding. The Vanguard Group, Inc. and State Street Global Advisors Australia Ltd. have highest stake in the company with a shareholding of ~4.99% and ~4.0%, respectively.

Recent business update

Through an ASX update dated 8 April 2024, the company posted an update about the publications of the secondary analyses and primary data as presented on AEGIS II Trial Data to the American College of Cardiology. CSL is focused on data assessment and there are no intent for a regulatory filing in the near term.

Outlook

In FY24, the company expects to register around 9-11% increase in revenue in constant currency and 13-17% rise in underlying NPATA to around USD 2.9 – 3.0 billion at constant currency.

For CSL Behring business segment, continued patient demand for Ig is expected in core indication and growth for HEMGENIX is expected in the second half, while continuing yield and plasma initiatives.

Share performance of CSL

CSL shares closed 1.17% lower at AUD 283.37 apiece on 10 April. In the past one year, CSL’s share price has decreased by 6.0%, and in the past three months, it has dropped by 2.0%.

The 52-week high of CSL is AUD 312.99, recorded on 6 June 2023, while the 52-week low is AUD 228.65, recorded on 30 October 2023.

CSL Daily Technical Chart, Source: REFINITIV

Note 1: Past performance is neither an Indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, and currency, is 10 April 2024. The reference data in this report has been partly sourced from REFINITIV.